According to a recent announcement by the German Center for Infection Research (DZIF), the Paul Ehrlich Institute, Federal Institute for Vaccines and Biomedical Drugs, has approved the clinical trial with the MVA-SARS-2-S vaccine against COVID-19.
The danger posed by the coronavirus SARS-CoV-2 will only be averted once a vaccination against the novel pathogen is available. Researchers worldwide are working on vaccines. Another candidate from Germany will soon be tested on humans.
Experts repeatedly point out that the corona pandemic will not be over until vaccines against the corona virus SARS-CoV-2 are available. Research is currently being conducted worldwide on corona vaccines. One of them may now be tested on humans in Germany.
Vaccine against COVID-19 being tested
The vector vaccine was developed by scientists of the DZIF and IDT Biologika GmbH and will be tested in the first clinical phase for its safety, tolerability and specific immune response against the new pathogen.
The clinical trial is scheduled to start in October with the recruitment of the first of the total of 30 study participants at the CTC North Medical Contract Institute at the University Medical Center Hamburg-Eppendorf (UKE).
“I congratulate the entire vaccine team of the DZIF on this rapid development of a promising candidate vaccine against SARS-CoV-2”, says Prof. Dr. Hans-Georg Kräusslich, Chairman of the DZIF.
Clinical trial approved
“We are pleased that the first clinical trial has now been approved and will start very soon and of course hope for good results,” said Kräusslich.
And Katharina Fegebank, Hamburg’s Senator for Science, Research, Equality and Districts, says in a statement from the UKE: “I am extremely pleased that Hamburg scientists can make a decisive contribution to effectively fighting the pandemic with their outstanding research work. One thing is clear: Only with excellent research and scientific expertise can we get the virus under permanent control”.
According to the information provided, this viral vector cannot reproduce, but the DNA sequence that has been introduced – the component of the corona virus – can simulate an infection and trigger the production of antibodies and T-cells.
The vaccine is a vector vaccine against the coronavirus SARS-CoV-2 developed at the Ludwig-Maximilians-University of Munich (LMU), in which the genetic information for a surface protein of the SARS-CoV-2 virus is incorporated into a modified and thus harmless smallpox virus (MVA).
The original MVA virus was generated at the LMU more than 30 years ago as a safe vaccine against smallpox and has already been successfully used for the development of a vaccine against the MERS coronavirus.
IDT Biologika GmbH, a company that produces biotechnological vaccines and pharmaceuticals, has now developed a cell line and a process for the large-scale production of highly purified MVA vector vaccines and has already completed the production and filling of the vaccine doses for the first clinical trial in humans.
“We are very pleased about the approval of the Paul-Ehrlich-Institute. In the past months, the vaccine was developed with our DZIF cooperation partners Prof. Dr. Gerd Sutter from the LMU and Prof. Dr. Stephan Becker from the Philipps University of Marburg. We are now testing the vaccine for its efficacy and safety,” explains Prof. Dr. Marylyn Addo, Head of Infectiology at the UKE, who is in charge of the clinical trial as the principal investigator.
WashingtonNewsday Health and Wellness.